Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Subject-Blind, Investigator-Blind, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy, Safety, and Tolerability of Rozanolixizumab in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

NCT03861481 is registered in ClinicalTrials.gov with UCB Biopharma S.P.R.L. as lead sponsor.

NCT NCT03861481
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03861481 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Subject-Blind, Investigator-Blind, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy, Safety, and Tolerability of Rozanolixizumab in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
Lead sponsor
UCB Biopharma S.P.R.L.
Phase
Phase 2
Overall status
Completed
Start date
March 26, 2019
Completion date
March 31, 2021
Enrollment
34 (actual)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

chronic inflammatory demyelinating polyradiculoneuropathy (cidp)